Grufity logo
Grufity logo
BLUE

BLUE - Bluebird Bio Inc Stock Price, Fair Value and News

$2350.00-170.00 (-6.75%)
Market Closed as of 29 Oct 2026, 04:00 pm ET

BLUE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BLUE Price Action

Last 7 days

-19.0%

Last 30 days

-20.6%

Last 90 days

-3.3%

Trailing 12 Months

43.3%

BLUE RSI Chart

BLUE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BLUE Valuation

Market Cap

32.8B

Price/Earnings (Trailing)

-164

Price/Sales (Trailing)

315.51

EV/EBITDA

-4.8K

Price/Free Cashflow

-142.33

BLUE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BLUE Fundamentals

BLUE Revenue

BLUE Earnings

BLUE Profitability

Free Cashflow Yield

-0.7%

BLUE Investor Care

Revenue & Growth

How Bluebird Bio Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025103.9M---
202445.7M54.9M53.1M83.8M
20234.0M9.4M21.7M29.5M
20224.7M6.1M5.1M3.6M
2021189.0M127.2M65.4M3.7M
202054.1M239.7M250.0M250.7M
201951.1M56.5M53.9M44.7M
201844.6M35.7M39.5M54.6M
201711.5M26.7M32.8M35.4M
20169.2M5.8M6.1M6.2M
201525.4M24.0M19.0M14.1M
201425.4M25.4M25.4M25.4M
20131.4M7.6M13.9M20.2M
2012746.5K611.0K475.5K340.0K
2011---882.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Bluebird Bio Inc

BLUE
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
 CEO
 WEBSITEbluebirdbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES323

Bluebird Bio Inc Frequently Asked Questions

BLUE is the stock ticker symbol of Bluebird Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Oct 29 2026, market cap of Bluebird Bio Inc is 32.8 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Thu Oct 29 2026, BLUE's PE ratio (Price to Earnings) is -164 and Price to Sales (PS) ratio is 315.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BLUE PE ratio will change depending on the future growth rate expectations of investors.